BGI Genomics
BGI Genomics is one of the world’s largest DNA sequencing service providers.
BGI Genomics, founded in August, 2008 and headquartered in Shenzhen, is a genomics R&D institution. The founder is Wang Jian. Listed on the SZSE on July 14, 2017, the company's major shareholders are BGI Genomics Co.,Ltd., Shenzhen Qianhai BGI Investment Enterprise (LP) and Shenzhen Heyu Gaolin Equity Investment Partnership (LP). Rivals that have direct and indirect competition with BGI Genomics include Kintor, HitGen, Aprea Therapeutics, BridgeBio Pharma, etc.
Cancer cell therapy company raised CNY 500 million in D round
Bh009 new drug project independently researched and developed by Beihai biological Co., Ltd. was approved by China's clinical trials
Xinyi biological completed 150 million round B financing, and Lilly Asia Fund led investment in Huachuang capital, hillhood venture capital and other follow-up investment
Another protein component special medical food was approved, and the total number of approved products increased to 57
Research
Healthcare, Technology, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Research
Consumer Staples, Real Estate, Consumer DiscretionaryTech for Global, Globalization Footprints of the Established and the New
BGI and Hanwei intelligent medical jointly launched mobile "two cancer" intelligent screening
Improving service quality and enabling industrial innovation!
Plan to raise $4 billion! Jingdong health runs IPO
Drug Innovator Asieris Nabs CNY 700 Million Series D
HaoYuan Chemexpress Files for IPO on the Star Market
Beijing Immunochina Pharmaceutical Closes Series C+ at CNY 100 Mn
Chinese Biotech Zai Laboratory Lands on HKEX after 3 Years' Listing on Nasdaq
Open Source, Open Mind: Baidu and LinkingMed Help Doctors in Medical Images
A Chinese startup, based on Baidu’s deep-learning open-source platform PaddlePaddle, is providing CT screening service to a Hunan-based hospital, hoping to facilitate the diagnosis process.
Mar 05, 2020 11:41 AM
AI-Based Drug Research Platform XtalPi Closes Series C at USD 318.8 Mn
Broncus Biotech Closes Series C of Multi-Tens Millions US Dollars
Top-Tier CDMO Heyuan China Closes Series C at over CNY 300 Mn
BGI Genomics Plans to Raise CNY 2 billion to Expand Diagnosis Project